title: [Immunotherapy of superficial bladder tumors in a hospital department].
abstract: Since 1988 27 patients with bladder cancer - in the T1, G1, G2 stage - have been treated by intra-cavitally applied BCG (Pasteur). The follow-up period was 12-62 months. There was no relapse in 18 cases (66%) in 4 cases (16%) increase the average relapse rate, in 5 cases the treatment was unsuccessful. These results suggest that the treatment is effective, affordable and occur few complications.
authors.forename: G
authors.initials: G
authors.lastname: Prekopp
authors.forename: E
authors.initials: E
authors.lastname: Rosdy
mesh_terms: D000287:Administration, Topical; D000368:Aged; D001500:BCG Vaccine / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D009367:Neoplasm Staging; D001749:Urinary Bladder Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy
chemical_list: D001500:BCG Vaccine
vernacular_title: Felületes hólyagtumorok immunoterápiája osztályunkon.